Gilead Sciences, Inc. vs Rhythm Pharmaceuticals, Inc.: SG&A Expense Trends

Gilead vs. Rhythm: A Decade of SG&A Expense Evolution

__timestampGilead Sciences, Inc.Rhythm Pharmaceuticals, Inc.
Wednesday, January 1, 201429830000001213000
Thursday, January 1, 201534260000003425000
Friday, January 1, 201633980000006311000
Sunday, January 1, 201738780000009518000
Monday, January 1, 2018405600000028080000
Tuesday, January 1, 2019438100000036550000
Wednesday, January 1, 2020515100000046125000
Friday, January 1, 2021524600000068486000
Saturday, January 1, 2022567300000092032000
Sunday, January 1, 20236090000000117532000
Monday, January 1, 20246091000000
Loading chart...

Unlocking the unknown

SG&A Expense Trends: Gilead Sciences vs. Rhythm Pharmaceuticals

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, Gilead Sciences, Inc. and Rhythm Pharmaceuticals, Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Gilead Sciences has seen a steady increase in SG&A expenses, growing by approximately 104%, reflecting its expansive market strategies and operational scale. In contrast, Rhythm Pharmaceuticals, a smaller player, has experienced a staggering increase of over 9,600% in the same period, indicating aggressive growth and investment in market penetration. This divergence highlights the different stages and strategies of these companies within the pharmaceutical landscape. As Gilead consolidates its market position, Rhythm is rapidly scaling its operations, offering a fascinating glimpse into the dynamics of pharmaceutical financial management.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025